Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 189.55

+3.5%

Dec 12 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (4401)	8/4/1997 10:20:00 AM
From: Henry Niman	of 32384

Rezulin (troglitazone) has now also been approved in Europe: LONDON, July 31 (Reuter) - Britain's Glaxo Wellcome Plc said on Thursday it had received approval from the UK's regulatory Medicines Control Agency to market Romozin (troglitazone), a drug for treating non-insulin dependent diabetes. This is the first regulatory approval for Romozin in Europe and the UK will now act as the reference member state under the European Commission's mutual recognition procedure. Romozin is the first of a new class of compounds that targets insulin resistance. Tests have shown that some diabetics can reduce or discontinue insulin while using troglitazone. Romozin has been co-developed by Glaxo in Europe under licence from Japan's Sankyo Co <4501.T> which discovered the compound. Glaxo Wellcome will market Romozin in Europe and other territories including South Africa and Israel. The Japanese firm has retained rights to market the drug in some European countries. Romozin (troglitazone) is marketed as Rezulin by Parke-Davis <WLA.N>and Sankyo in North America and as Noscal by Sankyo in Japan. 05:19 07-31-97

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next